Lung Cancer | Specialty

Registrational Trials for the FDA Approval of Trilaciclib

May 13th 2021

An expert in the management of small cell lung cancer gives an in-depth review of the study design, safety, and efficacy of the clinical trials that led to the FDA approval of trilaciclib for chemotherapy-induced myelosuppression.

Upcoming Live Broadcast to Feature Recent Data and Case Study in ALK+ Metastatic NSCLC

May 12th 2021

Dr. Le on Next Steps With Poziotinib in EGFR+ or HER2+ Exon 20 NSCLC

May 12th 2021

Xiuning Le, MD, PhD, discusses next steps with poziotinib (NOV120101, HM781-36B) in patients with EGFR-positive or HER2-positive exon 20–mutant non–small cell lung cancer.

TIL Immunotherapy Shows Promise as Second-Line Treatment of NSCLC

May 12th 2021

Investigators are studying LN-145, a novel immunotherapy developed from autologous tumor-infiltrating lymphocytes, as a potential new option for patients with unresectable or metastatic non–small cell lung cancer after disease progression on a checkpoint inhibitor and chemotherapy.

Osimertinib Preferred in Adjuvant and Frontline Metastatic EGFR+ NSCLC, But More Therapies Are Needed to Overcome Resistance

May 11th 2021

Sherri Cervantez, MD, discusses the utility of osimertinib in non–small cell lung cancer, as well as remaining questions regarding the treatment of patients who develop resistance to the third-generation EGFR inhibitor.

Liu Breaks Down the Use of Targeted and Immunotherapy Approaches in Early-Stage NSCLC

May 11th 2021

Findings from the pivotal phase 3 PACIFIC and ADAURA trials have not only led to paradigm shifts and served as the basis for ongoing research for patients with unresectable and resectable non–small cell lung cancer, respectively, but have emphasized the importance of distinguishing treatment options based on the presence or absence of an oncogenic driver.

NSCLC Paradigm Continues to Push Forward With Emerging Targets, but Predictive Biomarkers Are Limited

May 10th 2021

Nagashree Seetharamu, MD, MBBS, discusses emerging targets in non–small cell lung cancer and the limitations of current biomarkers.

Lurbinectedin Takes Center Stage in Second-line SCLC Treatment

May 10th 2021

Neil Morganstein, MD, discusses the impact of lurbinectedin on the SCLC treatment paradigm and future research directions with the agent in this population.

Fulfilling the Promise of Precision Medicine in EGFR-Mutant NSCLC

May 9th 2021

Edward S. Kim, MD, highlights efforts being made to overcome resistance to EGFR TKIs in patients with EGFR-mutated NSCLC and factors to consider when determining sequential treatment.

Frontline Durvalumab Plus Tremelimumab and Chemo Improves OS for Stage IV NSCLC

May 7th 2021

The combination of durvalumab plus tremelimumab and platinum-based chemotherapy resulted in a significant improvement in overall survival compared with chemotherapy alone in the frontline treatment of patients with stage IV non–small cell lung cancer.

Building Off the Success Seen With Immunotherapy Strategies in NSCLC

May 7th 2021

Erminia Massarelli, MD, MS, PhD, shares key updates in immunotherapy and targeted treatment for patients with NSCLC

FDA Approval Insights: Cemiplimab in Advanced PD-L1–High NSCLC and Advanced Basal Cell Carcinoma

May 6th 2021

Dr. Sezar and Dr. Stratigos discuss the FDA approvals of cemiplimab-rwlc in advanced non–small cell lung cancer and advanced basal cell carcinoma.

Future of SCLC Treatment Lies in Innovative Immunotherapy Combos

May 6th 2021

Ravi Salgia, MD, PhD, discusses pivotal trials that have shaken up the SCLC treatment paradigm and novel immunotherapy regimens under investigation.

Trilaciclib in SCLC: Mechanism of Action and Dosage

May 6th 2021

Jim Schwartz, RPh, provides key insights into the recent approval of trilaciclib and discusses how CDK4/6 inhibition potentially improves response to cytotoxic chemotherapy by protecting patients from myelosuppression.

Quadri Calls for Integration of Surgery Into Evolving Locally Advanced Lung Cancer Paradigm

May 6th 2021

Syed M. Quadri, MD, discusses the role of surgery in early-stage and locally advanced lung cancer, as well future directions with robotic and minimally invasive surgery.

Impact of Myelosuppression in Extensive-Stage SCLC

May 6th 2021

Ralph Boccia, MD, discusses myelosuppression with chemotherapy and highlights its impact on treatment outcomes and patient quality of life.

Frontline Atezolizumab Approved in Europe for PD-L1–High Metastatic NSCLC

May 5th 2021

The European Commission has approved atezolizumab for use as a frontline treatment in patients with metastatic non–small cell lung cancer whose tumors have a high PD-L1 expression and do not harbor EGFR or ALK aberrations.

Decker Details Key Updates in Radiation for Advanced NSCLC

May 5th 2021

Roy Decker, MD, PhD, discusses the utility of interventional radiology and SBRT in patients with oligometastatic disease and detailed ongoing clinical trials for NSCLC as they relate to radiation therapy.

Dr. Shafique on Selecting Between Selpercatinib and Pralsetinib in RET+ NSCLC

May 4th 2021

Michael Shafique, MD, discusses treatment considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.

Research Efforts Focus on Reducing Recurrence in Early-Stage EGFR-Mutant NSCLC

May 4th 2021

Edward S. Kim, MD, highlights the impact of osimertinib in the treatment of patients with EGFR-mutant non–small cell lung cancer, next steps with the agent, and the importance of early genetic testing to provide personalized care.